How does iron deficiency exacerbate heavy menstrual bleeding in women receiving anticoagulation therapy?

Iron Deficiency Does Not Directly Cause Heavy Menstrual Bleeding from Anticoagulation—Rather, It Is the Consequence

Iron deficiency is the result of heavy menstrual bleeding in anticoagulated women, not the cause—however, iron deficiency itself can perpetuate and worsen bleeding through impaired platelet function, creating a vicious cycle that must be broken with iron repletion. 1, 2

The Bidirectional Relationship

Primary Mechanism: Anticoagulation → HMB → Iron Deficiency

Anticoagulation-related reproductive tract bleeding (AC-RTB) affects 20-60% of menstruating individuals, with heavy menstrual bleeding (HMB) reported in 19-71% depending on the anticoagulant used 1. This excessive blood loss directly depletes iron stores, leading to iron deficiency with or without anemia (ID/IDA). The relationship is straightforward: anticoagulants impair hemostasis, menstrual blood loss increases, and iron stores become progressively depleted 3, 4.

Secondary Mechanism: Iron Deficiency → Platelet Dysfunction → Worsened Bleeding

Once iron deficiency develops, it creates a self-perpetuating cycle through impaired platelet function. Research demonstrates that iron deficiency causes arachidonic acid-induced platelet dysfunction, which increases menstrual blood loss and can be reversed with iron repletion 2. This means:

• Iron-deficient platelets aggregate less effectively in response to certain agonists
• The impaired platelet function compounds the anticoagulation effect
• Women experience heavier bleeding than would occur from anticoagulation alone
• Iron replacement therapy restores normal platelet aggregation patterns 2

Clinical Implications and Management Algorithm

Recognition of the Problem

The vast majority of iron deficiency in anticoagulated menstruating women goes undiagnosed. Only 9.2% of reproductive-aged females starting anticoagulation have ferritin checked within 90 days, and among those tested, 36.6% have ferritin ≤50 ng/mL 3. This represents a critical gap in care.

Essential Screening Approach

All patients with HMB on anticoagulation should be evaluated and treated for iron deficiency with or without anemia 1. The screening must include:

• Ferritin levels (not just hemoglobin)—ferritin ≤30 ng/mL indicates iron deficiency, even with normal hemoglobin 3
• Complete blood count with MCV
• Recognition that 19.7% of iron-deficient patients have hemoglobin ≥12 g/dL, making them "non-anemic" but still iron deficient 3

Breaking the Cycle: Treatment Priorities

Iron repletion is mandatory to interrupt the platelet dysfunction-bleeding cycle 1, 2. Treatment options include:

1. Oral iron therapy for mild-moderate deficiency
2. Intravenous iron infusion for:
   • Severe deficiency
   • Intolerance to oral iron
   • Need for rapid repletion
   • Malabsorption concerns 1
3. Packed red blood cell transfusion reserved for acute severe anemia with hemodynamic compromise 1

Concurrent Bleeding Management

Iron replacement alone is insufficient. Simultaneous management of the HMB itself is essential 1:

• Hormonal therapies (levonorgestrel IUD, progestin-only methods, combined hormonal contraceptives)
• Tranexamic acid for acute bleeding episodes
• Consider anticoagulant switching (apixaban has lower HMB risk than rivaroxaban) 1
• Procedural interventions (endometrial ablation) for refractory cases 1

Critical Pitfalls to Avoid

Do not assume normal hemoglobin excludes iron deficiency—nearly 20% of iron-deficient anticoagulated women have normal hemoglobin levels 3. Always check ferritin.

Do not treat iron deficiency without addressing the underlying HMB—the bleeding will continue to deplete iron stores faster than replacement can occur 4.

Do not discontinue or skip anticoagulation doses to manage bleeding—this increases recurrent VTE risk by up to fivefold 4. Instead, optimize anticoagulation choice and add bleeding management strategies.

Do not overlook the platelet dysfunction component—iron replacement is therapeutic, not just supportive, as it directly improves platelet function and reduces bleeding 2.

The Multidisciplinary Imperative

Management requires coordinated care between hematology and gynecology 1. The hematologist manages anticoagulation optimization and iron repletion; the gynecologist addresses menstrual bleeding through hormonal or procedural interventions. Neither specialty alone can adequately manage this complex interaction.